S Vlassak

Learn More
INTRODUCTION Previous small-molecule antiangiogenics have compromised chemotherapy dose intensity in breast cancer. We present a phase I trial of a novel selective agent, nintedanib, plus standard chemotherapy in early breast cancer. METHODS Her-2-negative breast cancer patients with tumours larger than 2 cm were eligible for dose-escalation trial(More)
  • 1